- In early September 2026, Verisk announced its U.S. Data Center Exposure Database, offering building-level geocoding, structural details, and operational attributes for more than 2,500 data center facilities to support underwriting, exposure management, and catastrophe modeling within Verisk Synergy Studio and Touchstone.
- This launch highlights how Verisk is broadening its risk analytics coverage into data centers, a growing concentration of infrastructure and insurance exposure.
- Next, we’ll examine how this new data center exposure database could influence Verisk’s investment narrative around advanced risk analytics platforms.
Capitalize on the AI infrastructure supercycle with our selection of the 55 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
Verisk Analytics Investment Narrative Recap
To own Verisk, you need to believe in the long term value of specialized insurance data and risk analytics platforms like Synergy Studio and Touchstone. The new U.S. Data Center Exposure Database fits that story but, on its own, does not materially change the near term picture, where a key catalyst is continued adoption of advanced analytics and a key risk is pressure on insurer IT and data budgets if industry conditions tighten.
The data center database is most directly tied to Verisk’s broader push around Synergy Studio, one of the newer platforms analysts already flag as a growth driver. By adding a complex, high value asset class such as data centers into these tools, Verisk is reinforcing the catalyst of deeper, more precise risk insights at a time when insurers are looking to connect exposure data across catastrophe models and underwriting workflows.
Yet against this product momentum, investors still need to watch the risk that insurer spending on analytics tightens if inflation and regulatory uncertainty keep pressure on underwriting results…
Read the full narrative on Verisk Analytics (it’s free!)
Verisk Analytics’ narrative projects $3.8 billion revenue and $1.3 billion earnings by 2029.
Uncover how Verisk Analytics’ forecasts yield a $237.71 fair value, a 28% upside to its current price.
Exploring Other Perspectives
Six fair value estimates from the Simply Wall St Community span roughly US$76.85 to US$277.85 per share, with views scattered across that full range. When you set those opinions against Verisk’s push to expand platforms like Synergy Studio, it underlines how differently investors can weigh product momentum versus the risk of insurers pulling back on analytics budgets, and why it is worth exploring several viewpoints before forming your own.
Explore 6 other fair value estimates on Verisk Analytics – why the stock might be worth as much as 50% more than the current price!
The Verdict Is Yours
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
- A great starting point for your Verisk Analytics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Verisk Analytics research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Verisk Analytics’ overall financial health at a glance.
Want Some Alternatives?
Opportunities like this don’t last. These are today’s most promising picks. Check them out now:
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
You can copy Bill Ackman and buy Netflix. Knowing why you did is the hard part.
Netflix case is interesting. The scariest competitor is the one that does not need to make money. Amazon can run video at a loss forever because it is really a Prime retention tool with a content budget attached. On the other hand there is Youtube.
Pershing Square hasn’t beaten the S&P over the last five years, though the long-run record is genuinely good. I like Ackman as a person. I enjoy listening to Ackman and that’s about where it ends for me.
Mitchell Lawler
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picks
Fresh 13F filings are where some investors go to find their next stock pick. The problem is it’s missing some of the most important details for making a good investment.
31
Sep 4, 2026
About NasdaqGS:VRSK
Verisk Analytics
Engages in the provision of data analytics and technology solutions to the insurance industry in the United States and internationally.
Fair value with limited growth.
Similar Companies
Market Insights
What 13F filings won’t tell you about a billionaire’s stock picksMI
Mitchell Lawler
Great earnings season, but are the earnings real?AN
Andrew Legget
Which payment stocks actually get paid?MI
Mitchell Lawler
Advertisement
Weekly Picks
Lou_Baseneseon Oncolytics Biotech·19 days ago
The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech
Fair Value:US$3.575.9% undervalued
66followersusers have followed this narrative
·1commentusers have commented on this narrative
·17likesusers have liked this narrative
AN
andrei9868on ServiceNow·22 days ago
The Platform Turning Enterprise Chaos into Autonomous Workflows
John_Ericon Vistra·6 days ago
Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here’s the $472 Million Reason They Disagree.
HarishPKon EverQuote·16 days ago
EverQuote and an Asymmetric Investment Opportunity
RecentlyUpdated Narratives
RockeTelleron Meeka Metals·about 6 hours ago
Meeka Metals: 1.2 Moz High-Grade Gold Producer – Open Pit Failure to Underground Transition?
RogueEPon Quanex Building Products·about 8 hours ago
The Market Is Pricing a Housing Cyclical. We See a Self-Funding Consolidator
Fair Value:US$33.3331.2% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
JO
John_Ericon Hamilton Lane·about 9 hours ago
Analysts Cut Their Targets. The Co-Chairman Cut a Check.
Popular Narratives
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
John_Ericon MercadoLibre·1 day ago
MercadoLibre and the Spreadsheet Trick That Decides Everything
Fair Value:US$3.68k46.2% undervalued
130followersusers have followed this narrative
·3commentsusers have commented on this narrative
·18likesusers have liked this narrative
ANAnalystConsensusTargeton NVIDIA·about 1 month ago
